# Hemab Therapeutics funding rounds and investors

As of 14 Oct 2026, Hemab Therapeutics has raised $157M across 1 verified round on record; latest: $157 million Series C led by Sofinnova Partners, announced 27 Oct 2025.

Hemab develops targeted therapies for bleeding disorders, focusing on conditions like Glanzmann Thrombasthenia and Von Willebrand Disease.

Website: https://hemab.com  
Headquarters: Cambridge, MA, USA & Copenhagen, Denmark  
Page: https://fireround.dev/companies/hemab.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-10-27 | Series C | $157 million | Sofinnova Partners | Access Biotechnology, Avoro Capital Advisors, Deep Track Capital, HealthCap, Invus, Maj Invest Equity, Novo Holdings, RA Capital Management, Rock Springs Capital | [healthcap.eu](https://www.healthcap.eu/media/hemab-therapeutics-announces-157-million-series-c-financing-to-advance-next-generation-treatments-for-underserved-bleeding-disorders) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.